We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




New Metabolomics Kit Enables Use with Specialized Mass Spectrometer

By LabMedica International staff writers
Posted on 26 Mar 2013
A state-of-the-art metabolomics-based research kit has been specially designed for use with a triple stage quadrupole mass spectrometer, enabling additional laboratories to use such kits.

Biocrates Life Sciences AG (Innsbruck, Austria) introduced “AbsoluteIDQ p150,” the new edition of its well-established line of metabolomics-based research kits. More...
The kit has been available for use with AB Sciex and Waters mass spectrometry systems, and has now been designed to also run on Thermo Scientific’s “TSQ Vantage” Triple Stage Quadrupole Mass Spectrometer, enabling more research labs to harness the power of targeted metabolite quantification with a ready-to-use kit system. Combined with a robust new ion source, second-generation ion optics, and hyperbolic quadrupoles, the “TSQ Vantage” mass spectrometer delivers both higher sensitivity and lower chemical noise.

AbsoluteIDQ p150 provides extensive metabolic information from a single targeted assay, quantifying 158 metabolites using a FIA-MS/MS method. It features the proprietary “MetIDQ” software, requires minute sample volumes (10 µL), and is suitable for use with a wide range of biological samples, making it an excellent choice with a cost-effective solution to measure endogenous metabolites under quality-controlled conditions in a researcher’s own laboratory. The Biocrates AbsoluteIDQ kits have been successfully applied in many different areas, including oncology, endocrinology, diabetes, nephrology, sepsis, and CNS disorders, in both clinical and pharmaceutical research. Biocrates mass spectrometry-based, standardized metabolomic kits provide multiplexing potential and superior accuracy and precision.

Related Links:
Biocrates




Gold Member
Neonatal Heel Incision Device
Tenderfoot
Online QC Software
Acusera 24•7
Steam Sterilizer
Hi Vac II Line
HPV Test
Allplex HPV28 Detection
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Characterization of EV separated by distinct methods (Photo courtesy of Yuanyuan Liu, Yanbin Guo et al. Engineering, doi.org/10.1016/j.eng.2025.12.009)

Liquid Biopsy Biomarkers May Improve Childhood Epilepsy Diagnosis

Childhood epilepsy remains a major neurological disorder with unmet needs for accurate, non-invasive biomarkers, as conventional tests such as electroencephalography and neuroimaging can have limited sensitivity... Read more

Molecular Diagnostics

view channel
Image: NeoCircle Study Synopsis (George, A.M., Chen, Y., Gladchuk, S. et al. EMBO Molecular Medicine (2026). DOI: 10.1038/s44321-026-00447-z)

Ultrasensitive MRD Blood Test Detects Early Breast Cancer Recurrence

SAGA Diagnostics (Morrisville, NC, USA), a company specializing in tumor-informed, blood-based cancer detection and precision medicine, announced the publication of a new study evaluating its Pathlight... Read more

Pathology

view channel
Image: Immune-related signals in routine bone marrow biopsy slides could help predict multiple myeloma outcomes and support more personalized treatment strategies (image credit: Shutterstock)

AI Tool Extracts Immune Signals from Biopsy to Inform Myeloma Therapy

Multiple myeloma is a bone marrow malignancy in which patients can respond very differently to the same treatments, making initial therapy decisions difficult. Clinicians must choose among options such... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.